2026年11月4日星期三
M
Rekod Semesta
Berita Pantas Global
US tech giants' hidden AI debt swells 90% to $3.2tn in 6 months— 日经 Nikkei AsiaFukushima tries to reinvent itself as hub for drones, robots and rockets— 日经 Nikkei AsiaJapan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei AsiaNew MUFG digital bank to forgo ATM cards in cybercrime safeguard— 日经 Nikkei AsiaJapan to bolster defenses with unified missile, artillery systems— 日经 Nikkei AsiaNTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei AsiaUS tech giants' hidden AI debt swells 90% to $3.2tn in 6 months— 日经 Nikkei AsiaFukushima tries to reinvent itself as hub for drones, robots and rockets— 日经 Nikkei AsiaJapan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei AsiaNew MUFG digital bank to forgo ATM cards in cybercrime safeguard— 日经 Nikkei AsiaJapan to bolster defenses with unified missile, artillery systems— 日经 Nikkei AsiaNTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei Asia

A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial

Sumber Nature 医学研究1 hari lalu
Ringkasan kandungan

Laman ini hanya menyediakan indeks tajuk dan ringkasan, kandungan penuh dan hak cipta adalah milik pihak penerbit asal, sila klik pautan asal untuk membaca.

Pergi ke artikel asal
Saluran berkaitan
Kesihatan
Kawasan berkaitan
Perspektif global
Bahasa teks asal
English
Nombor entri
health-05bcbb4d

Comments 0 comments

No comments yet. Be the first.

A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial · Rekod Semesta